

PERSONAL INFORMATION **Annalisa Ciabattini**



📍 Policlinico Le Scotte, V lotto piano -2
, V.le Bracci 4, 53100 Siena, Italy
☎ +39 0577 232901

✉ annalisa.ciabattini@unisi.it

WORK EXPERIENCE

2024-present
2021-2024

Associate Professor of Microbiology, University of Siena, Italy

Researcher RTD-B, Dept. Medical Biotechnology, University of Siena, Italy.

She is part of the "Microbial Immunology" group at the Laboratory of Molecular Microbiology and Biotechnology. She designs experiments, participates in the execution, analyzes the data and is responsible for the drafting of scientific publications. Research activity is currently focused on conducting two multicenter studies aimed at characterizing the immune response to vaccination against COVID-19 in healthy and fragile patients. She is supervisor of the activity of 2 Post Doc, 1 Junior Researcher, 1 Technologist, 1 PhD student and 4 Students. Teaching activity in the courses "General and Clinical Microbiology" and "Microbiology"

2004-2021

Technician, Dept. Medical Biotechnology, University of Siena, Italy

Research activity focused on the dynamics of the interaction between microorganism and host, with characterization of the host immune response and evaluation of protection from microbial challenge. Co-supervisor of 25 Master Degree students, and 4 PhD students

2020-2021

Contract Professor, Dept. Medical Biotechnology, University of Siena, Italy

Teaching activity in the course "General and Clinical Microbiology"

2001-2010

Contract Professor, Dept. Medical Biotechnology, University of Siena, Italy

Teaching activity in the courses "General and Clinical Microbiology", "Microbial immunity of oral cavity", "Interaction between oral bacteria and immune system".

EDUCATION AND TRAINING

13/07/2020

National Academic Qualification as Associate Professor, Microbiology and Clinical Microbiology (SC 06/A3)

13/01/2020

National Academic Qualification as Associate Professor, Microbiology (SC 05/I2)

1999-2002

PhD in Biotechnology, University of Siena, Italy;

Thesis "Gram-positive bacteria for mucosal vaccine delivery: *in vivo* and *in vitro* interactions with the immune system"

1993-1998

Master degree in Biological Sciences, University of Siena, Italy

110/110 *cum laude*

ADDITIONAL INFORMATION

Grants

2023

PI project RUNNERS-UP, University Research Plan 2023

2021-2025

Principal Investigator in the International project, "Pediatric Phase I/II age de-escalation dose finding study of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa" (PedVaciNTS), funded by European/Developing countries Clinical Trials Partnership (EDCTP)

2009

Exploration Grant entitled "Testing T-cell priming efficacy of mucosal adjuvants" in the context of the European project MUVAPRED

Scientific society

2021-present

Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM)

2017-present

Membro dell'Organismo preposto al Benessere degli Animali (OPBA)

2014-present

Membro della Società Italiana di Microbiologia (SIM)

2003-present

Membro della Società Italiana di Immunologia Clinica e Allergologia (SIICA).

Editorial Board

Reviewer Editor for *Frontiers in Immunology*

Publications

AC scopus profile. Articles published in last 5 years:

- [Ciabattini A*](#), Pettini E, Fiorino F, Polvere J, Lucchesi S, Coppola C, Costagli S, Pastore G, Sicuranza A, Tozzi M, Lippi A, Francesca Panza^{5,6}, Bocchia M, Alessandro Bucalossi⁴, Guido Garosi⁷, David Bennett⁸, Sonia Bernazzali⁹, Fabbiani M, Montagnani F and Medaglini D. **Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.** eBioMedicine 2025. (*Corresponding author)
- Lucchesi S, Montesi G, Polvere J, Fiorino F, Pastore G, Sambo M, Lusini M, Montagnani F, [Ciabattini A](#), Santoro F, Garosi G, Medaglini D. **Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene expression profile in low-responder hemodialysis patients".** In revisione a Frontiers in Immunology
- Roscioli E, Zucconi Galli Fonseca V, Soledad Bosch S, Paciello I, Maccari G, Batani G, Stazzoni S, Cardinali G, Tiseo G, Giordano C, Shen Y, Capoccia L, Ridelfi M, Troisi M, Manganaro N, Mugnaini C, Cardamone D, De Santi C, [Ciabattini A](#), Cerofolini L, Fragai M, Licastro D, Nicolau DP, Abdelraouf K, Barnini S, Menichetti F, Falcone M, Sala C, Kabanova A and Rappuoli R. **Anti-capsule human monoclonal antibodies protect against hypervirulent and pandrug-resistant Klebsiella pneumoniae.** In revisione a Nature
- Montesi G, Augello M, Polvere J, Marchetti G, Medaglini D, [Ciabattini A](#). **Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach.** J Transl Med. 2024 May 7;22(1):432. doi: 10.1186/s12967-024-05147-1.
- [Ciabattini A*](#); Pastore, G.; Lucchesi, S.; Montesi, G.; Costagli, S.; Polvere, J.; Fiorino, F.; Pettini, E.; Lippi, A.; Ancillotti, L.; Tumbarello, M.; Fabbiani, M.; Montagnani, F.; Medaglini, D. **Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine.** Cells. 2023 Jun 23;12(13):1706. doi: 10.3390/cells12131706 (*Corresponding author)
- Pettini E, [Ciabattini A](#), Pastore G, Polvere J, Lucchesi S, Fiorino F, Montagnani F, Bucalossi A, Tozzi M, Marotta G, Medaglini D. **A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses.** Blood Advances 2022. doi: 10.1182/bloodadvances.2021006599
- Vianello E.,Gonzalez-Dias P.,van Veen S.,Engele C.G.,Quinten E.,Monath T.P.,Medaglini D., VSV-EBOVAC Consortium (Agnandij S.T., Ahmed R. ,Anderson J, Auderset F., Bejon P, Borgianni L, Brosnahan J, [Ciabattini A](#) et al). **Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.** The Lancet Microbe 2022
- Fiorino F¹, Sicuranza A¹, [Ciabattini A](#)¹, Santoni A, Pastore G, Simoncelli M, Polvere J, Galimberti S, Auddino S, Baratè C, Montagnani F, Sammartano V, Bocchia M, Medaglini D. **The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose.** Biomedicines 2021; 15;9(10):1480. doi: 10.3390/biomedicines9101480. (*equally contributed*)
- [Ciabattini A*](#), Pastore G¹, Fiorino F, Polvere J, Lucchesi S, Pettini E, Auddino S, Rancan I, Durante M, Miscia M, Rossetti B, Fabbiani M, Montagnani F, Medaglini D*. **Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine.** Front Immunol 2021 Sep 28;12:740708. doi: 10.3389/fimmu.2021.740708. (*co-corresponding author; *equally contributed*)
- Pettini E, Pastore G, Fiorino F, Medaglini D and [Ciabattini A*](#). **Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?** Vaccines (Basel) 2021 Mar 20;9(3):289. doi: 10.3390/vaccines9030289. (*corresponding author)
- [Ciabattini A](#), Garagnani P, Santoro F, Rappuoli R, Franceschi C, Medaglini D. **Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population.** Seminars in Immunopathology 2020, 42, 5:619-634. doi: 10.1007/s00281-020-00821-0
- Lucchesi S., Furini S, Medaglini D, [Ciabattini A*](#). **From bivariate to multivariate analysis of cytometric data: Overview of computational methods and their application in vaccination studies.** Cytometry A 2020. 8, 1, 138. doi: 10.3390/vaccines8010138. (*corresponding author)

Siena, 05/02/2025